Could AstraZeneca shares benefit from new cancer drug?
The pharmaceutical giant’s new breast cancer drug could revolutionise treatment
Over the weekend, AstraZeneca PLC unveiled positive trial data for its new breast cancer drug, which suggests it could be a game-changer for patients.
Experts say the drug antibody-based drug Enhertu could change the way in which breast cancer is treated.
Results demonstrated that the product doubled the progression-free survival rates of patients with late-stage breast cancer compared with chemotherapy treatment. The product was jointly developed with Japanese company Daiichi Sankyo.
In the trial of 550 patients, the drug reduced the risk of the disease progressing by 50%. It works by targeting hormone sensitive tumours known as HER2-targetable.
"Today's results represent a pivotal moment demonstrating the potential for Enhertu to redefine the treatment of HER2-targetable cancers,” said Susan Galbraith, executive vice president, Oncology R&D, at AstraZeneca.
“[The trial] validates targeting the lower end of the spectrum of HER2 expression, since Enhertu reduced the risk of disease progression or death across all types of patients in the trial by half and reduced the risk of death by over a third.
"We must now evolve the way we classify and treat metastatic breast cancer to ensure these patients are effectively diagnosed and treated."
AstraZeneca drug could be a ‘multi-blockbuster’
Breast cancer is now the most commonly diagnosed form of the disease across the world, recently overtaking lung cancer. Over two million cases were diagnosed in 2020 and almost 685,000 people died of the disease, according to AstraZeneca.
According to AstraZeneca, sales of Enhertu, excluding the Japanese market, were $426 million in 2021. However, the company thinks the product could become a “multi-blockbuster” as it could also be approved to treat other types of cancer, which are hormone sensitive, including certain types of lung cancer.
"As far as breast cancer goes, I'd say at least in the next few years, I'm pretty sure Enhertu is going to kind of finish revolutionising the treatment paradigm," Tara Hansen, a consultant at Informa Pharma Custom Intelligence, told Reuters.
Analysts at Jefferies expect peak global sales of $2.5 billion in breast cancer patients and a total of around $6.6 billion of peak sales in all cancer treatment indications.
Could AstraZeneca shares have further to run?
Shares in the drug giant dipped 2.89% to £101.44p on Monday – likely on profit-taking as the stock has performed strongly over the past few years. The drug giant has also benefited from strong sales of its Covid vaccine, although at the recent results management said that this fillip was set to wane.
The shares have risen 24% since last December and are trading near their five-year highs. However, there could be further mileage in them. Broker Berenberg recently set a price target of £120 for them and trading is expected to be strong this year, despite the waning of the Covid vaccine fillip. Investors can be forgiven for taking some profits, nevertheless.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.